Skip to content

Public FDA record

Z-1301-2018: Binding Site Optilite Beta-2-Microglobulin Urine Kit, Ref LK043.L.OPT.A, IVD. The firm name on the label

Recall record Z-1301-2018 for The Binding Site Group, Ltd.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1301-2018
Company in FDA record
The Binding Site Group, Ltd.
FDA record creation date
Apr 3, 2018
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

The product is not meeting the antigen excess protection claim of up to 760mg/L, as stated in the Instructions for Use.

Source facts

Action
The recalling firm notified their U.S. location by letter dated 3/6/2018 via email on 3/9/2018.
Initiated
2018-03-09
Root cause
Under Investigation by firm
Terminated
2020-06-22
Distribution
US Distribution was made to CA. There was no foreign/military/government distribution.
Recall number
Z-1301-2018
Recall status
Terminated
CDRH record ID
162483
FDA record created
2018-04-03
Recall event number
79499

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗